Global pharmaceutical major Lupin Limited will present the Phase 1a clinical trial data of its experimental oncology drug LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 to be held in Chicago, Illinois from May 30 to June 3, 2025.

The presentation titled “A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors” will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session at Poster Board #422 on June 2, 2025, from 1:30 PM to 4:30 PM CDT.

Key clinical findings

  • LNP7457 was found to be generally safe and well-tolerated in patients with advanced or metastatic solid tumors.

  • It showed a favorable pharmacokinetic and pharmacodynamic (PK/PD) profile, with no food-related effects on pharmacokinetics.

  • The maximum tolerated dose was identified and will inform the recommended Phase 2 dosage, based on safety, efficacy, and existing preclinical data.

Vinita Gupta, CEO of Lupin, commented: “We are delighted to share the initial results from Phase I study of our PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. We are committed to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to-treat cancers.”

Next steps in development

Lupin indicated that LNP7457 is unique within its class as a SAM-competitive PRMT5 inhibitor, and continues to demonstrate promising safety and tolerability. The company plans to advance the molecule into Phase 1b trials in India, aiming to explore its efficacy in treating cancers with significant unmet medical needs.

The trial is registered under CTRI/2023/07/054753, and the presentation can be accessed online via the ASCO Abstract link.

Disclaimer: This article is for informational purposes only. Business Upturn does not provide any investment advice or drug recommendations. All data regarding clinical trials and pharmaceuticals should be evaluated by medical professionals and regulators.